Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Udhayvir Singh Grewal, Harsh Patel, Shiva Jashwanth Gaddam, Aakash Rajendra Sheth, Subhash Chandra Garikipati & Glenn Morris Mills. (2022) National trends in hospitalizations among patients with colorectal cancer in the United States. Baylor University Medical Center Proceedings 35:2, pages 153-155.
Read now
Read now
Simon B. Zeichner, Christine G. Kohn & Daniel A. Goldstein. (2016) Economics of ramucirumab for metastatic colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 733-745.
Read now
Read now
Donna Lawrence, Michael Maschio, Kevin J. Leahy, Simon Yunger, Jacob C. Easaw & Milton C. Weinstein. (2013) Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Journal of Medical Economics 16:12, pages 1387-1398.
Read now
Read now
Jetty A. Overbeek, Zhongyun Zhao, Myrthe P. P. van Herk-Sukel, Beth L. Barber, Sue Gao & Ron M. C. Herings. (2011) Costs of hospital events in patients with metastatic colorectal cancer. Journal of Medical Economics 14:5, pages 656-661.
Read now
Read now
Articles from other publishers (20)
Kung-Jeng Wang & Hendry Lukito. (2023) Lifespan and medical expenditure prognosis for cancer metastasis - a simulation modeling using semi-Markov process. Computer Methods and Programs in Biomedicine 234, pages 107509.
Crossref
Crossref
Hilary K. WhithamAubrey E. GillilandSarah A. CollierElaine Scallan Walter & Sandra Hoffmann. (2022) Direct Outpatient Health Care Costs Among Commercially Insured Persons for Common Foodborne Pathogens and Acute Gastroenteritis, 2012–2015. Foodborne Pathogens and Disease 19:8, pages 558-568.
Crossref
Crossref
Nazim Bhimani, Geoffrey YM. Wong, Charles Molloy, Mbathio Dieng & Thomas J. Hugh. (2022) Cost of colorectal cancer by treatment type from different health economic perspectives: A systematic review. European Journal of Surgical Oncology.
Crossref
Crossref
Carolina Reyes, Nicole M. Engel-Nitz, Stacey DaCosta Byfield, Arliene Ravelo, Sarika Ogale, Tim Bancroft, Amy Anderson, May Chen & Matthew Matasar. (2019) Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer. The Oncologist 24:9, pages 1209-1218.
Crossref
Crossref
Aleix Martínez-Pérez, Carmen Payá-Llorente & Arturo García-Lozano. 2019. Emergency Surgical Management of Colorectal Cancer. Emergency Surgical Management of Colorectal Cancer
31
42
.
Nicola Huxley, Louise Crathorne, Jo Varley-Campbell, Irina Tikhonova, Tristan Snowsill, Simon Briscoe, Jaime Peters, Mary Bond, Mark Napier & Martin Hoyle. (2017) The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technology Assessment 21:38, pages 1-294.
Crossref
Crossref
Afsaneh Barzi, Heinz-Josef Lenz, David I. Quinn & Sarmad Sadeghi. (2017) Comparative effectiveness of screening strategies for colorectal cancer. Cancer 123:9, pages 1516-1527.
Crossref
Crossref
Rohan C. ParikhXianglin L. DuMorgan O. RobertDavid R. Lairson. (2017) Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients. Journal of Managed Care & Specialty Pharmacy 23:1, pages 64-73.
Crossref
Crossref
Taulant Muka, David Imo, Loes Jaspers, Veronica Colpani, Layal Chaker, Sven J. van der Lee, Shanthi Mendis, Rajiv Chowdhury, Wichor M. Bramer, Abby Falla, Raha Pazoki & Oscar H. Franco. (2015) The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. European Journal of Epidemiology 30:4, pages 251-277.
Crossref
Crossref
Tanja Mesti, Biljana Mileva Boshkoska, Mitja Kos, Metka Tekav?i?Janja Ocvirk. (2015) The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement. Radiology and Oncology 49:2.
Crossref
Crossref
Steven R. Alberts, Tiffany M. Yu, Robert J. Behrens, Lindsay A. Renfro, Geetika Srivastava, Gamini S. Soori, Shaker R. Dakhil, Rex B. Mowat, John P. Kuebler, George P. Kim, Miroslaw A. Mazurczak & John Hornberger. (2014) Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer. PharmacoEconomics 32:12, pages 1231-1243.
Crossref
Crossref
Swee Sung Soon, Whay-Kuang Chia, Mun-ling Sarah Chan, Gwo Fuang Ho, Xiao Jian, Yan Hong Deng, Chuen-Seng Tan, Atul Sharma, Eva Segelov, Shaesta Mehta, Raghib Ali, Han-Chong Toh & Hwee-Lin Wee. (2014) Cost-Effectiveness of Aspirin Adjuvant Therapy in Early Stage Colorectal Cancer in Older Patients. PLoS ONE 9:9, pages e107866.
Crossref
Crossref
Nicola Silvestris, Bruno Vincenzi, Anna Elisabetta Brunetti, Fotious Loupakis, Emanuela Dell'Aquila, Antonio Russo, Mario Scartozzi, Riccardo Giampieri, Stefano Cascinu, Vito Lorusso, Giuseppe Tonini, Alfredo Falcone & Daniele Santini. (2014) Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics 15:13, pages 1701-1715.
Crossref
Crossref
Veena ShankaranDavid MummyLisel KoeplAasthaa BansalDana K. MirickElaine Yu, Rob Morlock, Sarika Ogale & Scott D. Ramsey. (2014) Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer. The Oncologist 19:8, pages 892-899.
Crossref
Crossref
Hassan Serrier, H?l?ne Sultan-Taieb, Dani?le Luce & Sophie Bejean. (2013) Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France. The European Journal of Health Economics 15:6, pages 661-673.
Crossref
Crossref
Christine Kriza, Martin Emmert, Philip Wahlster, Charlotte Niederl?nder & Peter Kolominsky-Rabas. (2013) Cost of Illness in Colorectal Cancer: An International Review. PharmacoEconomics 31:7, pages 577-588.
Crossref
Crossref
Saurabh Ray, Vijayveer Bonthapally, Nicole M Meyer, Jeffrey D Miller, Machaon M BonafedeSuellen M Curkendall. (2013) Direct medical costs associated with different lines of therapy for colorectal cancer patients. Colorectal Cancer 2:2, pages 121-134.
Crossref
Crossref
J. Zeidler, A. Lange, S. Braun, R. Linder, S. Engel, F. Verheyen & J.-M. Graf von der Schulenburg. (2013) Die Berechnung indikationsspezifischer Kosten bei GKV-Routinedatenanalysen am Beispiel von ADHSCalculation of disease-related costs in claims data analyses with the example of attention-deficit hyperactivity disorder. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 56:3, pages 430-438.
Crossref
Crossref
Edo Bottacchi, Giovanni Corso, Piera Tosi, Massimo Veronese Morosini, Giuseppe De Filippis, Laura Santoni, Gianluca Furneri & Cristina Negrini. (2012) The cost of first-ever stroke in Valle d’Aosta, Italy: linking clinical registries and administrative data. BMC Health Services Research 12:1.
Crossref
Crossref
JA Overbeek, Z Zhao, MPP Van Herk-Sukel, BL Barber & RMC Herings. (2012) Cardiovascular comorbidities among patients with metastatic colorectal cancer. journal of Cancer Therapeutics and Research 1:1, pages 4.
Crossref
Crossref